BRAF and neoplasm: In this study, we explored, for the first time (to our knowledge), a proof-of-concept intratumoral heterogeneity-based transcriptome biomarker of prognosis and potential response in patients treated with anti-EGFR agents along with the clinically established criteria of RAS/BRAF wild-type status and tumor sidedness.